TROPION-PanTumor01研究Dato-DXd在TNBC患者中的应用,2021年1月8日第一次分析数据,通过盲目独立中心评估的在可评估的21例接受Dato-DXd[6 mg / kg(n = 19)或8 mg / kg(n = 2)]治疗的患者中,初步客观缓解率(ORR)为43%。...
■研究背景:Datopotamab-deruxtecan(Dato DXd)是一种抗体-药物结合物,由人源化的抗TROP2 IgG1单克隆抗体组成,通过可裂解的四肽连接子和拓扑异构酶-I抑制剂(喜树碱类衍生物DXd)连接。第一阶段TROPIONPanTumor01研究的初步结果表明,Dato DXd在非小细胞肺癌(NSCLC)(Meric Bernstam,ASCO 2021)和三阴性乳腺癌(TN...
结果:根据盲态独立中心评估(BICR):在所有TNBC患者中ORR为34%,疾病控制率(DCR)为77%。 BICR评估的所有TNBC患者的抗肿瘤疗效 BICR评估:既往未接受过以拓扑异构酶Ⅰ抑制剂ADC药物治疗的TNBC患者ORR可达52%,DCR为81%。 BICR评估的既往未...
Conclusions: Preliminary results showed that Dato-DXd demonstrates promising antitumor activity with a manageable safety profile in patients with previously treated advanced/metastatic TNBC; confirmatory studies in patients with breast cancer are warranted....
The median duration of response was not evaluable in the HR+/HER2– BC cohort and 16.8 months in the TNBC cohort. The median progression-free survival in patients with HR+/HER2– BC and TNBC was 8.3 and 4.4 months, respectively. All-cause treatment-emergent adverse events (TEAEs; any ...
近日,国际肿瘤顶级期刊《Journal of Clinical Oncology》在线发表了Dato-DXd I期TROPION-PanTumor01研究结果3,进一步证实了Dato-DXd在经治晚期HR+/HER2-和TNBC乳腺癌患者中具有令人鼓舞的抗肿瘤活性和可控的安全性。基于此,医脉通特邀浙江大学医学院附属第一医院傅佩芬教授撷取研究重点进行精彩解读和点评,以飨读者。
subgroup of patients. The overall safety profile of datopotamab deruxtecan in TNBC in TROPION-PanTumor01 was consistentwith what has been previously reported with no new safety signals. Treatment emergent adverse events(TEAEs) occurring in ≥15% of patients included nausea, stomatitis, vomiting,...
Here we present the updated results for patients with advanced TNBC (data cutoff: July 22, 2022). Materials and Methods TROPION-PanTumor01 (NCT03401385) is a phase 1, multicenter, open-label, 2-part, dose-escalation and -expansion study...
TROPION-PanTumor01研究Dato-DXd在TNBC患者中的应用,2021年1月8日第一次分析数据,通过盲目独立中心评估的在可评估的21例接受Dato-DXd[6 mg / kg(n = 19)或8 mg / kg(n = 2)]治疗的患者中,初步客观缓解率(ORR)为43%。观察到5个已确认的完全或部分缓解(CR / PR),还有4个正在等待确认的CR / PR。